GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » Cash Flow from Financing

Adicon Holdings (HKSE:09860) Cash Flow from Financing : HK$0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Adicon Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Adicon Holdings paid HK$0 Mil more to buy back shares than it received from issuing new shares. It received HK$0 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0 Mil from paying cash dividends to shareholders. It received HK$0 Mil on other financial activities. In all, Adicon Holdings spent HK$0 Mil on financial activities for the six months ended in Dec. 2023.


Adicon Holdings Cash Flow from Financing Historical Data

The historical data trend for Adicon Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicon Holdings Cash Flow from Financing Chart

Adicon Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
637.43 -583.08 4.16 951.78

Adicon Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial - - - - -

Adicon Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Adicon Holdings's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Adicon Holdings's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adicon Holdings  (HKSE:09860) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Adicon Holdings's issuance of stock for the six months ended in Dec. 2023 was HK$0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Adicon Holdings's repurchase of stock for the six months ended in Dec. 2023 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Adicon Holdings's net issuance of debt for the six months ended in Dec. 2023 was HK$0 Mil. Adicon Holdings received HK$0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Adicon Holdings's net issuance of preferred for the six months ended in Dec. 2023 was HK$0 Mil. Adicon Holdings paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Adicon Holdings's cash flow for dividends for the six months ended in Dec. 2023 was HK$0 Mil. Adicon Holdings received HK$0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Adicon Holdings's other financing for the six months ended in Dec. 2023 was HK$0 Mil. Adicon Holdings received HK$0 Mil on other financial activities.


Adicon Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Adicon Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicon Holdings (HKSE:09860) Business Description

Traded in Other Exchanges
Address
No. 208, Zhenzhong Road, West Lake, Zhejiang, Hangzhou, CHN
Adicon Holdings Ltd is one of the top three independent clinical laboratory or ICL, service providers in China. The company offers comprehensive and best-in-class testing services primarily to hospitals and health check centers through an integrated network of 33 self-operated laboratories across China. The high quality of its services is backed by its strong performance in terms of international accreditation and comprehensive testing menu. Its testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests. It has three major service platforms. Among them, the inspection service platform consists of clinical, pathology, reproductive genetic, genetic, and mass spectrometry laboratories.
Executives
Cap V General Partner, L.p. 2201 Interest of corporation controlled by you
Cap V, L.l.c. 2201 Interest of corporation controlled by you
Carlyle Asia Partners V, L.p. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii Gp L.l.c. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii L.l.c. 2201 Interest of corporation controlled by you
Cg Subsidiary Holdings L.l.c. 2201 Interest of corporation controlled by you
Pearl Group Limited 2101 Beneficial owner
Tc Group Cayman Investment Holdings L.p. 2201 Interest of corporation controlled by you
Tc Group Cayman Investment Holdings Sub L.p. 2201 Interest of corporation controlled by you
The Carlyle Group Inc. 2201 Interest of corporation controlled by you
Lin Feng
Mega Stream Limited
Trident Trust Company (hk) Limited 2301 Trustee
Ingenuity Capital Holdings Limited 2201 Interest of corporation controlled by you
Corelink Group Limited

Adicon Holdings (HKSE:09860) Headlines

No Headlines